Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

401 recalls · Class II, newest first

Risk Class IClass IIClass III
Status OngoingCompletedTerminated
Year 20262025202420232022 2012 All years
Cause Sterility / contaminationNitrosamine impurityChemical / undeclaredParticulate / foreign matterLabeling / mix-upcGMP deviationMicrobial contamination All causes
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1328-01 D-085-2013
Class II · Moderate risk

Thyro-Tab 0.300 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-084-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1331-01 D-083-2013
Class II · Moderate risk

Thyro-Tab 0.137 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-082-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1324-01 D-081-2013
Class II · Moderate risk

Thyro-Tab 0.125 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-080-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1330-01 D-079-2013
Class II · Moderate risk

Thyro-Tab 0.112 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-078-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1329-01 D-077-2013
Class II · Moderate risk

Thyro-Tab 0.088 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-076-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1321-01 D-075-2013
Class II · Moderate risk

Thyro-Tab 0.050 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-074-2013
Class II · Moderate risk

Naproxen Tablets USP

Labeling: Label Mix-Up: Bottles labeled as Naproxen Tablets USP, 500 mg, 100-count may contain 90-count Pravastatin Sodium Tablets, 40 mg.

Terminated Labeling / mix-up Glenmark Generics Inc., USA NDC 68462-190-01 D-1701-2012
Class II · Moderate risk

Mercaptopurine Tablets

Failed USP Dissolution Test Requirements: The recalled lots do not meet the specification for dissolution.

Terminated Dissolution failure Prometheus Laboratories Inc. NDC 49884-922-02 D-1659-2012
Class II · Moderate risk

Mylan

Failed USP Content Uniformity Requirements: OOS result reported on retained samples.

Terminated Wrong potency / content Mylan LLC. NDC 0378-2045-01 D-066-2013
Class II · Moderate risk

Paclitaxel Injection

The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

Terminated Particulate / foreign matter Hospira Inc. D-1682-2012
Class II · Moderate risk

Methotrexate Injection

The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

Terminated Particulate / foreign matter Hospira Inc. NDC 61703-408-41 D-1681-2012
Class II · Moderate risk

Cytarabine Injection

The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

Terminated Particulate / foreign matter Hospira Inc. NDC 61703-303-46 D-1680-2012
Class II · Moderate risk

Carboplatin Injection

The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are beig recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

Terminated Particulate / foreign matter Hospira Inc. NDC 61703-339-50 D-1679-2012
Class II · Moderate risk

Oxygen

CGMP Deviations; no identity or purity testing on incoming oxygen gas, and lack of documentation

Terminated cGMP deviation Oklahoma Respiratory Care Inc D-1445-2012
Class II · Moderate risk

Little Remedies For Tummys

Subpotent (Single Ingredient) Drug: This product is being recalled because of sub-potency of the sennosides.

Terminated Wrong potency / content Medtech Products, Inc. D-1673-2012
Class II · Moderate risk

ZEE Antiseptic Wipes

Microbial contamination of Non Sterile Product; contamination with Burkholderia cepacia (manufacturer)

Terminated Microbial contamination Dukal Corp. D-1675-2012

Recalls by year